Seer (SEER) Q2 FY26 earnings call

Seer, Inc. continues to advance its Proteograph technology with significant scientific validation and a strong cash position, despite facing revenue challenges from macroeconomic headwinds and elongated sales cycles. The company is focusing on commercial optimization under new leadership and expects a ramp in revenue growth in the second half of the year, driven by scientific data and strategic partnerships.